The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide-Reference-Cited by-同舟云学术

The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide

Published:2017-07-27 Issue:22 Volume:123 Page:4356-4362
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Bandari Jathin¹^ORCID,Ayyash Omar M.¹,Turner Robert M.¹,Jacobs Bruce L.¹,Davies Benjamin J.¹

Affiliation:

1. Department of Urology; University of Pittsburgh School of Medicine; Pittsburgh Pennsylvania

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. Increase in prostate cancer distant metastases at diagnosis in the United States;Hu;JAMA Oncol,2017

2. Exciting therapies ahead in prostate cancer;Gohil;P T,2015

3. Medivation Inc 10-K report, referencing collaboration with Astellas Pharmaceuticals Inc https://www.sec.gov/Archives/edgar/data/1011835/000119312513084368/d467813d10k.htm

4. Johnson and Johnson https://www.sec.gov/Archives/edgar/data/200406/000020040616000071/form10-k20160103.htm

5. Medivation Inc https://www.sec.gov/Archives/edgar/data/1011835/000156459016013460/mdvn-10k_20151231.htm

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of non-research payments from pharmaceutical companies to urologists in Japan between 2016 and 2019;International Urogynecology Journal;2023-02-01

2. Understanding Prescribing Differences Between Urologists and Medical Oncologists in the Management of Advanced Prostate Cancer;Urology Practice;2023-01

3. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide;Urology;2021-12

4. Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review;British Journal of Cancer;2021-10-01

5. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies;Urology;2021-02